Thomas Ciulla MD PC

[ad_1] Recently published: https://t.co/5IyRrMAdlc “Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications” Sustained release #drugdelivery may shift treatment paradigms & improve #glaucoma outcomes. #eye https://t.co/JLqoDGIu4W [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @ModernRetina: The U.S. Centers for Medicare and Medicaid Services code is effective July 1 and will enhance access to Xipere, the only… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with uveitis: Effect of disease characteristics on clinical outcomes | IOVS | ARVO Journals https://t.co/UgGLPY5nln [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @OphthTimes: @BauschLomb annonced today it has received a permanent J-Code for triamcinolone acetonide injectable suspension (Xipere). #… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Age adjusted differences in vascular and metabolic biomarkers between patients with open-glaucoma and healthy controls | IOVS | ARVO Journals https://t.co/EeqmtDgS6e [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with uveitis: Integrated analysis of two clinical trials | IOVS | ARVO Journals https://t.co/bMb8UImn5o [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] National physician survey on clinical practice patterns for the treatment of noninfectious uveitis | IOVS | ARVO Journals https://t.co/UMNEwjPTjd [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.